Article info

Download PDFPDF

Extended report
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

Authors

  1. Correspondence to Dr John Gerry Coghlan, Cardiology Department, Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK; Gerry.Coghlan{at}nhs.net
View Full Text

Citation

Coghlan JG, Galiè N, Barberà JA for the AMBITION investigators, et al
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

Publication history

  • Received July 18, 2016
  • Revised December 2, 2016
  • Accepted December 3, 2016
  • First published December 30, 2016.
Online issue publication 
June 12, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.